EP4096649A4 - Compositions and methods for providing chemoprotective effects - Google Patents

Compositions and methods for providing chemoprotective effects

Info

Publication number
EP4096649A4
EP4096649A4 EP21747296.8A EP21747296A EP4096649A4 EP 4096649 A4 EP4096649 A4 EP 4096649A4 EP 21747296 A EP21747296 A EP 21747296A EP 4096649 A4 EP4096649 A4 EP 4096649A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
providing
chemoprotective effects
chemoprotective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21747296.8A
Other languages
German (de)
French (fr)
Other versions
EP4096649A1 (en
Inventor
Serhat Gumrukcu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
G Tech Bio LLC
Original Assignee
G Tech Bio LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G Tech Bio LLC filed Critical G Tech Bio LLC
Publication of EP4096649A1 publication Critical patent/EP4096649A1/en
Publication of EP4096649A4 publication Critical patent/EP4096649A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
    • C12Y603/02002—Glutamate-cysteine ligase (6.3.2.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP21747296.8A 2020-01-31 2021-02-01 Compositions and methods for providing chemoprotective effects Pending EP4096649A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062968906P 2020-01-31 2020-01-31
PCT/US2021/016041 WO2021155351A1 (en) 2020-01-31 2021-02-01 Compositions and methods for providing chemoprotective effects

Publications (2)

Publication Number Publication Date
EP4096649A1 EP4096649A1 (en) 2022-12-07
EP4096649A4 true EP4096649A4 (en) 2024-04-17

Family

ID=77079986

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21747296.8A Pending EP4096649A4 (en) 2020-01-31 2021-02-01 Compositions and methods for providing chemoprotective effects

Country Status (4)

Country Link
EP (1) EP4096649A4 (en)
JP (1) JP2023512287A (en)
CN (1) CN115605084A (en)
WO (1) WO2021155351A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020195A1 (en) * 1992-04-01 1993-10-14 Fox Chase Cancer Center Method and recombinant cells for providing increased resistance of hematopoietic progenitor cells to toxicity of chemotherapeutic agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109168A0 (en) * 1993-04-01 1994-06-24 Univ Columbia A retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs
WO2015009884A1 (en) * 2013-07-18 2015-01-22 The Hamner Institutes Cell culture media formulations comprising an activator of nad-dependent protein deacteylase and ueses thereof
CA3082404A1 (en) * 2017-11-15 2019-05-23 Weird Science Llc Methods and compositions for non-myeloablative bone marrow reconstitution
BR112021000620A2 (en) * 2018-07-15 2021-04-20 Enochian BioPharma, Inc. methods and compositions using recombinant dendritic cells for cancer therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020195A1 (en) * 1992-04-01 1993-10-14 Fox Chase Cancer Center Method and recombinant cells for providing increased resistance of hematopoietic progenitor cells to toxicity of chemotherapeutic agents

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BOTTA DIANNE ET AL: "Modulating GSH Synthesis Using Glutamate Cysteine Ligase Transgenic and Gene-Targeted Mice", DRUG METABOLISM REVIEWS, vol. 40, no. 3, 9 January 2008 (2008-01-09), UNITED STATES, pages 465 - 477, XP093101728, ISSN: 0360-2532, Retrieved from the Internet <URL:http://dx.doi.org/10.1080/03602530802186587> DOI: 10.1080/03602530802186587 *
GÜMRÜKCÜ SERHAT ET AL: "Glutamate-Cysteine Ligase Modifier Subunit Overexpression Confers Resistance Against Busulfan", 1 May 2022 (2022-05-01), XP093101680, Retrieved from the Internet <URL:https://seraphinstitute.org/wp-content/uploads/2022/03/Publication10.pdf> [retrieved on 20231115] *
HARKEY M A ET AL: "OVEREXPRESSION OF GLUTATHIONE-S-TRANSFERASE, MGSTII, CONFERS RESISTANCE TO BUSULFAN AND MELPHALAN", CANCER INVESTIGATION, TAYLOR & FRANCIS INC, US, vol. 23, no. 1, 1 January 2005 (2005-01-01), pages 19 - 25, XP009053374, ISSN: 0735-7907 *
HIYAMA NORIKO ET AL: "Glutamate-cysteine ligase catalytic subunit is associated with cisplatin resistance in lung adenocarcinoma", JAPANESE JOURNAL OF CLINICAL ONCOLOGY, vol. 48, no. 4, 1 April 2018 (2018-04-01), pages 303 - 307, XP093101749, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892860/pdf/hyy013.pdf> DOI: 10.1093/jjco/hyy013 *
See also references of WO2021155351A1 *

Also Published As

Publication number Publication date
JP2023512287A (en) 2023-03-24
WO2021155351A1 (en) 2021-08-05
EP4096649A1 (en) 2022-12-07
CN115605084A (en) 2023-01-13

Similar Documents

Publication Publication Date Title
IL280693A (en) Compositions and methods for improving library enrichment
IL275539A (en) Compositions and methods for inhibiting aldh2 expression
GB202013432D0 (en) Compositions
IL286587A (en) D-metyrosine compositions and methods for preparing same
GB202111040D0 (en) Compositions and methods
EP4212162A4 (en) Lipid composition
EP4138879A4 (en) Methods and compositions
EP4084784A4 (en) Compositions and methods
GB202004677D0 (en) Methods and compositions
GB202014160D0 (en) Senolytic compounds and compositions
EP4096649A4 (en) Compositions and methods for providing chemoprotective effects
IL308402A (en) Methods and compositions for radioprotection
GB202110091D0 (en) Methods and compositions
GB202105461D0 (en) Compositions
GB202015836D0 (en) Compositions
GB202214719D0 (en) Compositions and methods
IL311218A (en) Pah-modulating compositions and methods
IL310092A (en) Compositions and methods
IL309079A (en) Methods and compositions
GB202116554D0 (en) Methods and compositions
GB202113904D0 (en) Methods and compositions
GB202110572D0 (en) Compositions and methods
GB202105367D0 (en) Methods and compositions
GB202211117D0 (en) Compositions and methods for non-immunogenecity
GB202101962D0 (en) Methods and compositions

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220830

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230516

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: G TECH BIO LLC

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GUMRUKCU, SERHAT

A4 Supplementary search report drawn up and despatched

Effective date: 20240315

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/52 20060101ALI20240311BHEP

Ipc: C12N 9/00 20060101ALI20240311BHEP

Ipc: A61K 38/53 20060101ALI20240311BHEP

Ipc: A61K 35/12 20150101ALI20240311BHEP

Ipc: A61K 31/255 20060101AFI20240311BHEP